| Title |
Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon
|
|---|---|
| Published in |
Current Obesity Reports, March 2018
|
| DOI | 10.1007/s13679-018-0300-4 |
| Pubmed ID | |
| Authors |
Gitanjali Srivastava, Caroline Apovian |
| Abstract |
Obesity is a global health crisis with detrimental effects on all organ systems leading to worsening disease state and rising costs of care. Persons with obesity failing lifestyle therapies need to be escalated to appropriate pharmacological treatment modalities, medical devices, and/or bariatric surgery if criteria are met and more aggressive intervention is needed. The progression of severe obesity in the patient population coupled with related co-morbidities necessitates the development of novel therapies for the treatment of obesity. This development is preceded by increased understanding of the underpinnings of energy regulation and neurohormonal pathways involved in energy homeostasis. Though there are approved anti-obesity drugs available in the USA, newer drugs are now in the pipeline for development given the urgent need. This review focuses on anti-obesity drugs in the pipeline including centrally acting agents (setmelanotide, neuropeptide Y antagonist [velneperit], zonisamide-bupropion [Empatic], cannabinoid type-1 receptor blockers), gut hormones and incretin targets (new glucagon-like-peptide-1 [GLP-1] analogues [semaglutide and oral equivalents], amylin mimetics [davalintide, dual amylin and calcitonin receptor agonists], dual action GLP-1/glucagon receptor agonists [oxyntomodulin], triple agonists [tri-agonist 1706], peptide YY, leptin analogues [combination pramlintide-metreleptin]), and other novel targets (methionine aminopeptidase 2 inhibitor [beloranib], lipase inhibitor [cetilistat], triple monoamine reuptake inhibitor [tesofensine], fibroblast growth factor 21), including anti-obesity vaccines (ghrelin, somatostatin, adenovirus36). With these new drugs in development, anti-obesity therapeutics have potential to vastly expand allowing better treatment options and personalized approach to obesity care. |
X Demographics
The data shown below were collected from the profiles of 51 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 24 | 47% |
| Mexico | 2 | 4% |
| Colombia | 2 | 4% |
| Argentina | 1 | 2% |
| Chile | 1 | 2% |
| El Salvador | 1 | 2% |
| Unknown | 20 | 39% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 40 | 78% |
| Practitioners (doctors, other healthcare professionals) | 6 | 12% |
| Scientists | 3 | 6% |
| Science communicators (journalists, bloggers, editors) | 2 | 4% |
Mendeley readers
The data shown below were compiled from readership statistics for 353 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 353 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 59 | 17% |
| Student > Ph. D. Student | 42 | 12% |
| Student > Bachelor | 38 | 11% |
| Researcher | 33 | 9% |
| Student > Postgraduate | 19 | 5% |
| Other | 63 | 18% |
| Unknown | 99 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 91 | 26% |
| Pharmacology, Toxicology and Pharmaceutical Science | 36 | 10% |
| Biochemistry, Genetics and Molecular Biology | 30 | 8% |
| Agricultural and Biological Sciences | 24 | 7% |
| Nursing and Health Professions | 9 | 3% |
| Other | 45 | 13% |
| Unknown | 118 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 78. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 March 2024.
All research outputs
#556,204
of 25,732,188 outputs
Outputs from Current Obesity Reports
#48
of 427 outputs
Outputs of similar age
#12,678
of 348,371 outputs
Outputs of similar age from Current Obesity Reports
#7
of 16 outputs
Altmetric has tracked 25,732,188 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 427 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 40.3. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 348,371 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 56% of its contemporaries.